Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Xiangyu Medical Co.,Ltd (688626.SS)
CNY45.30
+0.58 (+1.30%)
CN SHH Healthcare Medical - Specialties
Address
Middle Section of Diku Avenue 456300
Anyang, FJ, CN
Anyang, FJ, CN
CEO
Yong Zheng He
Website
xyyl.com
IPO
2021-03-31
ISIN CNE100005394
Description
Xiangyu Medical Co.,Ltd engages in the research and development, manufacture, and marketing of rehabilitation and physiotherapy equipment in China. It provides various therapy such as smart occupational, electro, sport, rehab, cold and heat, gait training device, hydrotherapy, air compression, phototherapy, traction table, magnetic, CPM, occupational, shock wave and ultrasound, massage, treatment table, tilt table, therapy, micro and shock wave therapy. The company was incorporated in 2002 and is based in Anyang, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY45.30
+0.58 (+1.30%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.59
Float Shares
143.14M
Free Float %
92.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.03% | -10.48% | -12.35% | -23.70% | +9.97% | -15.04% | +35.55% | +16.84% | -48.08% | +14.73% | +14.73% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
45.30
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.82
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Specialties: +8.3%+3.3% Q1'26: +3.8% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-22.7% Q1'26: +6.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+12.1% Q1'26: -6.8% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+9.7% Q1'26: +10.8% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+4.0% Q1'26: +4.0% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%-1.1% ★ Q1'26: +0.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×5.14× ★ Q1'26: 8.15× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
523.50M
est: 523.00M (+0.1%)
|
488.53M
est: 581.00M (-15.9%)
|
744.81M
est: 747.91M (-0.4%)
|
743.53M
est: 687.00M (+8.2%)
|
767.75M
est: 793.00M (-3.2%)
|
862.26M
847.86M – 876.66M
+8.7% YoY
|
985.53M
955.37M – 1.02B
+14.3% YoY
|
1.13B
1.11B – 1.14B
+14.2% YoY
|
| EBITDA |
234.15M
est: 126.31M (+85.4%)
|
149.59M
est: 140.32M (+6.6%)
|
267.69M
est: 218.09M (+22.7%)
|
149.21M
est: 200.33M (-25.5%)
|
110.87M
est: 231.24M (-52.1%)
|
251.43M
247.24M – 255.63M
+8.7% YoY
|
287.38M
278.59M – 296.17M
+14.3% YoY
|
328.32M
325.10M – 331.54M
+14.2% YoY
|
| EBIT |
222.78M
est: 110.80M (+101.1%)
|
133.53M
est: 123.09M (+8.5%)
|
250.28M
est: 192.14M (+30.3%)
|
113.13M
est: 176.49M (-35.9%)
|
74.79M
est: 203.72M (-63.3%)
|
221.51M
217.82M – 225.21M
+8.7% YoY
|
253.18M
245.43M – 260.93M
+14.3% YoY
|
289.25M
286.42M – 292.09M
+14.2% YoY
|
| Net Income |
201.90M
est: 187.98M (+7.4%)
|
125.47M
est: 144.72M (-13.3%)
|
227.14M
est: 176.17M (+28.9%)
|
102.94M
est: 100.30M (+2.6%)
|
78.16M
est: 63.27M (+23.5%)
|
93.62M
91.58M – 95.65M
+48.0% YoY
|
117.79M
104.84M – 130.74M
+25.8% YoY
|
146.08M
142.91M – 149.25M
+24.0% YoY
|
| SGA |
140.42M
est: 157.88M (-11.1%)
|
175.89M
est: 175.39M (+0.3%)
|
210.41M
est: 217.22M (-3.1%)
|
274.02M
est: 199.53M (+37.3%)
|
132.71M
est: 230.31M (-42.4%)
|
250.43M
246.25M – 254.61M
+8.7% YoY
|
286.23M
277.47M – 294.99M
+14.3% YoY
|
327.01M
323.80M – 330.21M
+14.2% YoY
|
| EPS |
1.35
est: 1.26 (+7.1%)
|
0.79
est: 0.97 (-18.6%)
|
1.44
est: 1.12 (+28.6%)
|
0.66
est: 0.65 (+1.5%)
|
0.51
est: 0.41 (+24.4%)
|
0.61
0.59 – 0.62
+48.0% YoY
|
0.76
0.68 – 0.85
+25.8% YoY
|
0.95
0.93 – 0.97
+24.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-55.32M
OE per share TTM
-0.38
Owner's Yield
-0.68%
Maintenance CapEx ratio
127.58%
Maint CapEx / Avg PPE
67.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 13 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 241.0K | 0.06% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 19.3K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 8.6K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 952.6K | 0.06% |
| 5 | Vanguard ESG International Stock ETF VSGX | 0.00% | 12.4K | 0.10% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.10M | 0.05% |
| 7 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 1.5K | 0.22% |
| 8 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 4.6K | 0.22% |
| 9 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 2.5K | 0.22% |
| 10 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 1.1K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
111.1K
Shares Outstanding
154.19M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fan Duan | Head of the Big Data Platform | — | male |
| Hongfeng Jin | Financial Director | — | male |
| Junling Guo | Deputy GM, Director & Board Secretary | — | female |
| Ke Zhou | Head of Scenario Simulation | — | male |
| Yongzheng He | Chairman, GM & Technical Director | — | male |
| Zhang Jie | Head of Embedded Software of R&D Center | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688626.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
